Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update
11 mai 2023 08h00 HE
|
Daré Bioscience, Inc.
Conference Call and Webcast Today at 4:30 p.m. ET 2023 Anticipated Milestones: Sildenafil Cream, 3.6% for Female Sexual Arousal Disorder Phase 2b Clinical Study Topline DataXACIATO™ First...
Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023
04 mai 2023 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%
20 avr. 2023 08h00 HE
|
Daré Bioscience, Inc.
Phase 1 Thermography Study Quantitative Data Expected to Complement Patient Reported Outcome Data Collected in the Exploratory Phase 2b RESPOND At-Home Study Topline Data for the Exploratory Phase 2b...
David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, Inc., to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany
19 avr. 2023 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company’s Chief Scientific Officer, David Friend,...
Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therapy
18 avr. 2023 08h00 HE
|
Daré Bioscience, Inc.
Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal...
Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference
17 avr. 2023 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update
30 mars 2023 08h00 HE
|
Daré Bioscience, Inc.
Conference Call and Webcast Today at 4:30 p.m. ET 2022 Daré Key Portfolio Accomplishments: License Agreement with Organon to Commercialize XACIATOTMOvaprene® IDE Approval for Pivotal Contraceptive...
Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023
23 mars 2023 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at...
Daré Bioscience to Present at the 35th Annual Roth Conference
01 mars 2023 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1
22 févr. 2023 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the start of a Phase 1 study evaluating its development...